Cell & Gene Therapy Tracker identifies opportunities for cell and gene therapies and other high-priced, rare disease therapies, with a focus on development and licensing.
Cell & Gene Therapy Tracker
Assessment of pricing, reimbursement, and HTA decisions by product across markets
Information on publicly disclosed contract terms for CGT/CAR-T therapies by market and by product
Summary of access for therapies by market, price relative to index by country, and summary of key HTA decisions by market (e.g., durability, price)
Summary of pricing for standard of care products for chronic conditions (e.g., SMA, hemophilia, ERTs, cystic fibrosis, hATTR, PNH) that currently have pipeline gene therapy products, including standard of care vs. gene therapy pricing trends, along with potential gene therapy price comparisons
Learn More About our Insights and Sign Up for Access.